Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Davis signs ephedra ban.

This article was originally published in The Tan Sheet

Executive Summary

"California is doing the job that the federal government won't - acting to save lives and protect consumers," state Senator Jackie Speier (D) says of law banning ephedrine alkaloid-containing supplements going into effect Jan. 1, 2004. With Oct. 12 signature by outgoing Gov. Gray Davis (D), California joins Illinois, New York in barring the botanical from consumer supplement sales. Of prospects of national action, Speier's office says "observers believe that the strength of the supplement industry is keeping the FDA from taking meaningful action at the federal level." Another Speier-sponsored bill (SB 779) requiring mandatory quarterly adverse-event reporting by supplement manufacturers and distributors is in the Assembly health committee, to be addressed in 2004...

You may also be interested in...



Arnold Says “Hasta La Vista, Baby” To Health Department Supplement List

California schools will not be barred from accepting scholarships from companies that manufacture dietary supplements, following Governor Arnold Schwarzenegger's veto of a bill that would have authorized the state health department to create a list of banned supplements

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel